Neuland Laboratories Ltd.

NSE: NEULANDLAB | BSE: 524558 | ISIN: INE794A01010 | Industry: Pharmaceuticals
| Expensive Performer
15135.0000 626.00 (4.31%)
NSE Jan 07, 2026 15:31 PM
Volume: 60,558
 

15135.00
4.31%

Neuland Laboratories Ltd Q2FY17 Result Review

BOB Capital Markets Ltd.
Amalgamation Scheme: The scheme involves issue of fresh equity shares by NLL to NHSPL and NPRPL which would increase NLL's equity by 25.6%. Promoter holding would change from 51.68% to 41.29 % post-merger. This would likely come into effect from Q2FY18. The amalgamation is aimed at building stronger business and financials, obtain tax benefits by clubbing R&D; services required for CMS business & better operational convenience. Going forward, we expect NLL to enjoy high margins led by strong...
Number of FII/FPI investors increased from 248 to 257 in Dec 2025 qtr.
More from Neuland Laboratories Ltd.
Recommended